Product image of Minerva (Cyproterone Acetate, Ethinylestradiol) supplied by GNH India

Minerva

Active Ingredient:
Cyproterone Acetate, Ethinylestradiol
Origin:
EU

Minerva (Cyproterone Acetate, Ethinylestradiol)

Cyproterone acetate and ethinylestradiol, the active ingredients in Minerva, are a combined oral contraceptive presented as an oral tablet for oral use. It prevents pregnancy and treats androgen‑dependent conditions such as acne and hirsutism in women of reproductive age.

GNH India supplies Minerva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for export to EU and other markets. Timely logistics and post‑delivery support are also part of the service offering.

Manufacturer / TM Owner

Bayer Ag

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Minerva, a combined oral contraceptive, is indicated for several hormone‑related conditions.

  • Contraception: Prevents pregnancy by suppressing ovulation and altering cervical mucus and endometrial lining.
  • Acne: Reduces androgen‑driven skin lesions in women, improving facial and body acne.
  • Hirsutism: Decreases excessive hair growth associated with androgen excess.
  • Menstrual regulation: Helps establish predictable menstrual cycles and reduces menstrual‑related symptoms.

How It Works

  • Cyproterone acetate binds to progesterone receptors, providing progestogenic and anti‑androgenic activity while suppressing luteinizing hormone release. Ethinylestradiol supplies estrogenic stimulation, stabilizing the endometrium and enhancing negative feedback on the hypothalamic‑pituitary axis. Together they inhibit the mid‑cycle gonadotropin surge, preventing follicular development and ovulation, and induce cervical mucus and endometrial changes that reduce fertilisation and implantation.

Side Effects

Minerva may cause a range of adverse reactions, which are grouped by frequency and severity.

Common Side Effects

  • Nausea
  • Headache
  • Breast tenderness
  • Spotting between periods
  • Weight gain
  • Mood changes

Serious or Rare Side Effects

  • Venous thromboembolism (deep‑vein thrombosis, pulmonary embolism)
  • Stroke or transient ischemic attack
  • Myocardial infarction
  • Severe liver dysfunction or jaundice
  • Allergic reactions including anaphylaxis
  • Hyperkalaemia, especially with potassium‑sparing diuretics

Precautions & Warnings

Before prescribing Minerva, clinicians should evaluate the following safety considerations.

  • Contraindications: Avoid use in women with a history of thromboembolic disorders, stroke, or myocardial infarction.
  • Smoking: Do not prescribe to women over 35 who smoke, due to increased cardiovascular risk.
  • Blood pressure: Monitor hypertensive patients closely, as oral contraceptives may elevate blood pressure.
  • Liver disease: Use with caution in active liver disease; severe hepatic impairment is a contraindication.
  • Pregnancy: Not for use during pregnancy (Category X) and must be discontinued if pregnancy occurs.
  • Store at ambient temperature: Keep below 25 °C in the original packaging, protected from moisture.

Avoid Interactions

Minerva can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid)

  • Rifampicin, carbamazepine, phenytoin, St. John’s wort: Enzyme inducers that markedly reduce contraceptive hormone levels.
  • Protease inhibitors (e.g., ritonavir): Increase hormone concentrations, raising the risk of thrombotic events.
  • Anticoagulants (warfarin): May diminish anticoagulant effect, requiring closer monitoring.
  • Antiepileptic drugs (phenobarbital, primidone): Decrease oral contraceptive efficacy.

Moderate Interactions (Monitor Closely)

  • Antifungals (ketoconazole) and macrolide antibiotics (erythromycin): Can raise plasma hormone levels, potentially increasing side‑effect risk.
  • Selective serotonin reuptake inhibitors (SSRIs): May exacerbate mood‑related side effects.

Frequently Asked Questions

Minerva is a combined oral contraceptive that is prescribed to prevent pregnancy and to treat androgen‑dependent conditions such as acne and hirsutism in women of reproductive age.

Cyproterone acetate provides progestogenic and anti‑androgenic activity, while ethinylestradiol supplies estrogenic stimulation. Together they suppress the hypothalamic‑pituitary release of gonadotropins, preventing ovulation, and they modify cervical mucus and the endometrium to reduce the chance of fertilisation and implantation.

The dosing regimen for Minerva is determined by the prescribing clinician. Typically, the product is taken as one tablet daily at the same time each day, but the exact schedule should follow the healthcare professional’s instructions.

Minerva is classified as Pregnancy Category X, meaning it must not be used during pregnancy because it can cause fetal harm. It is also not recommended for breastfeeding women, as the hormones may pass into breast milk and affect the infant.

To order Minerva, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Minerva contains cyproterone acetate, which adds anti‑androgenic activity not present in many other estrogen‑progestin combinations. This makes it particularly useful for treating acne and hirsutism, while still offering reliable contraception comparable to other approved combined oral contraceptive products.

Minerva tablets should be stored at ambient temperature, below 25 °C, in the original blister pack or container. Protect them from excess moisture and direct sunlight to maintain potency throughout the shelf life.

Minerva is taken orally as a tablet. The usual practice is to swallow one tablet each day, preferably at the same time each day, with or without food, following the schedule prescribed by the healthcare provider.

Serious risks include venous thromboembolism, stroke, myocardial infarction, severe liver disease, and allergic reactions such as anaphylaxis. Women should seek immediate medical attention if they experience symptoms like sudden chest pain, shortness of breath, severe abdominal pain, or signs of a severe allergic reaction.

Minerva is contraindicated in women with a history of thromboembolic events, stroke, myocardial infarction, uncontrolled hypertension, active liver disease, known or suspected pregnancy, or in smokers over 35 years of age. It should also be avoided in individuals with known hypersensitivity to any of its components.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Cyproterone Acetate, Ethinylestradiol

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT